Is there a late-breaker submission for ECCMID 2019?
Yes, we will have a late-breaker submission. Dates and terms & conditions will be communicated in January. We suggest you sign up for our newsletter here or follow us on Twitter to not miss any information.
When do we get notified about the results of submitted abstracts?
The results will be communicated in late-January 2019, but before the early-bird registration deadline.
I've noticed that for abstract submission is mandatory to be a ECCMID member. Is this correct?
You don’t need to be a member to submit an abstract, but you need an ESCMID account, that can be created here:
Are ‘Trials in Progress’ permitted to be submitted to ECCMID?
If you are running a ‘Trial in Progress’, in which results are only expected after the regular abstract deadline (28 November 2018), please rather submit your abstract including results in the “Late Breaker” abstract call (spring 2019) than without results in the regular call.
Are agencies allowed to submit abstracts on behalf of the authors?Yes agencies can submit abstracts, kindly note that you need an ESCMID account to submit an abstract for 2019, that can be generated here. Submitters will be informed about the outcome of the abstract, they are kindly requested to forward this information to all involved authors.
Is there a limit to the number of authors per abstract? We do not have a limit of authors per abstract, but would not recommend more than 30 persons, due to the readability of the abstract. Study groups can also be added separately.
If I submit my abstract for ePoster, do I need to register for the congress?
ePoster only also needs to be linked to a valid registration, but no formal presentation onsite is needed.
Will it be possible to withdraw already accepted abstracts (until a certain date) for ECCMID 2019?
Abstracts can be withdrawn until 10 days before the congress, when they go public. Kindly note that your abstract might still appear in the printed programme, depending on the time of withdrawal.
Do you accept posters on topics like access/reimbursement studies on antibiotics?
Yes we do accept such abstracts, you can send studies from every part of the world.
Do you allow encore abstract submissions to be submitted to your ECCMID congress?
We cannot accept encores for ECCMID.
Only original material not published prior to the 3.4.19
Will you accept abstracts of narrative literature review?
We can accept literature review, but only with a case-report.
Are you accepting case reports or just research projects?
We do accept case reports. Please use the abstract submission for submitting original data.
I wonder whether you accept abstract in systematic review, meta-analysis and networ meta-analysis?
Yes we do, please submit your abstract for 2019 by using the official submission system.
We are about to launch a public health alert either via briefing note or public health bulletin – would it still be possible to submit an abstract on the incident in a wider context and including additional data?
Yes, this is possible. Please submit your abstract for 2019 by using the official submission system.
Do you accept abstracts in which only a part of the results will be published before 3.4.19 for the submission?
Yes, we do.
Do abstracts that are submitted to the congress get an impact factor?
There is no impact factor for abstract submitted to ECCMID.
How many abstracts can be submitted by author?
An author can submit as many abstract as he wants. There is no limitation. This includes also co-authorship.
For case reports: can the proposed template Background/Materials/Results/Conclusion be replaced by Background/case report/Conclusions.
Yes this is possible, as long as the downloaded template is used, as it is coded.
Can we use brand names?
Brand names should be avoided. However, if they are essential parts of the research project they should be capitalized with trademark symbol (for example: Rocephin®). The manufacturer of the specific test/assay/pharmaceutical compound should be always stated. Abbreviations are accepted if the full name of the test/assay/pharmaceutical compound is previously specified.